FDA has granted Fast Track designation to selinexor, Karyopharm Therapeutics Inc.’s first in class, oral SINE compound, for the treatment of patients with diffuse large B-cell lymphoma who have received at least two prior therapies and are not eligible for high dose chemotherapy with stem cell rescue or CAR-T therapy.
A new model aims to change the standard of care around medical debt by addressing the financial toll of cancer using a multidisciplinary, tumor board model approach. Now, recent five-year data shows that it’s working.
